{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:13:58Z","timestamp":1780470838311,"version":"3.54.1"},"reference-count":224,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>The Canadian Rheumatology Association (CRA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) have collaborated to update the recommendations for the management of spondyloarthritis (SpA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>A working group was assembled and consisted of the SPARCC executive committee, rheumatologist leaders from SPARCC collaborating sites, Canadian rheumatologists from across the country with an interest in SpA (both academic and community), a rheumatology trainee with an interest in SpA, an epidemiologist\/health services researcher, a member of the CRA executive, a member of the CRA therapeutics committee, and a patient representative from the Canadian Spondylitis Association. An extensive review was conducted of literature published from 2007 to 2014 involving the management of SpA. The working group created draft recommendations using multiple rounds of Web-based surveys and an in-person conference.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Recommendations for the management of SpA were created. Part II: Specific Management Recommendations addresses management with nonpharmacologic methods, nonsteroidal anti-inflammatories and analgesics, disease-modifying antirheumatic drugs, antibiotics, tumor necrosis factor inhibitors, other biologic agents, and surgery. Also included are 10 modifications for application to juvenile SpA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>These recommendations were developed based on current literature and applied to a Canadian healthcare context. It is hoped that implementation of these recommendations will promote best practices in the treatment of SpA.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.141001","type":"journal-article","created":{"date-parts":[[2015,2,16]],"date-time":"2015-02-16T01:09:16Z","timestamp":1424048956000},"page":"665-681","source":"Crossref","is-referenced-by-count":43,"title":["2014 Update of the Canadian Rheumatology Association\/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations"],"prefix":"10.3899","volume":"42","author":[{"given":"Sherry","family":"Rohekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley M.L.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigil","family":"Haroon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bessette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianne","family":"Mosher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mallinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carter","family":"Thorne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D.","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Inman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2015,2,15]]},"reference":[{"key":"2018112909340808000_42.4.665.1","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3899\/jrheum.141000","article-title":"2014 Update on the Canadian Rheumatology Association\/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada","volume":"42","author":"Rohekar","year":"2014","journal-title":"J Rheumatology"},{"key":"2018112909340808000_42.4.665.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes066"},{"key":"2018112909340808000_42.4.665.3","first-page":"1899","article-title":"The Cochrane review of physiotherapy interventions for ankylosing spondylitis","volume":"32","author":"Dagfinrud","year":"2005","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/acr.20415","article-title":"Exercise programs in trials for patients with ankylosing spondylitis: do they really have the potential for effectiveness?","volume":"63","author":"Dagfinrud","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2018112909340808000_42.4.665.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203148"},{"key":"2018112909340808000_42.4.665.6","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2018112909340808000_42.4.665.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200180"},{"key":"2018112909340808000_42.4.665.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.24585"},{"key":"2018112909340808000_42.4.665.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.21444"},{"key":"2018112909340808000_42.4.665.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-004-0451-3"},{"key":"2018112909340808000_42.4.665.11","first-page":"316","article-title":"Predictors of longterm outcome in ankylosing spondylitis","volume":"30","author":"Doran","year":"2003","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.12","first-page":"1420","article-title":"Predictors of the progression of functional disability in patients with ankylosing spondylitis","volume":"29","author":"Ward","year":"2002","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.13","doi-asserted-by":"publisher","DOI":"10.3109\/03009749609080003"},{"key":"2018112909340808000_42.4.665.14","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-010-9771-9"},{"key":"2018112909340808000_42.4.665.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110641"},{"key":"2018112909340808000_42.4.665.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202608"},{"key":"2018112909340808000_42.4.665.17","doi-asserted-by":"publisher","DOI":"10.1002\/art.20985"},{"key":"2018112909340808000_42.4.665.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029611"},{"key":"2018112909340808000_42.4.665.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075309"},{"key":"2018112909340808000_42.4.665.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-0963-y"},{"key":"2018112909340808000_42.4.665.21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"2018112909340808000_42.4.665.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq078"},{"key":"2018112909340808000_42.4.665.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep393"},{"key":"2018112909340808000_42.4.665.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.21054"},{"key":"2018112909340808000_42.4.665.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201370"},{"key":"2018112909340808000_42.4.665.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201252"},{"key":"2018112909340808000_42.4.665.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.23275"},{"key":"2018112909340808000_42.4.665.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350512"},{"key":"2018112909340808000_42.4.665.29","first-page":"88","article-title":"Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy","volume":"17","author":"Luukkainen","year":"1999","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909340808000_42.4.665.30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.8.767"},{"key":"2018112909340808000_42.4.665.31","doi-asserted-by":"publisher","DOI":"10.1097\/00004728-199607000-00002"},{"key":"2018112909340808000_42.4.665.32","first-page":"659","article-title":"Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging","volume":"23","author":"Braun","year":"1996","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.33","first-page":"719","article-title":"Efficacy of sacroiliac corticosteroid injections in patients with inflammatory spondyloarthropathy: results of a 6 month controlled study","volume":"27","author":"Hanly","year":"2000","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.34","doi-asserted-by":"publisher","DOI":"10.1080\/j.1600-0455.2002.430415.x"},{"key":"2018112909340808000_42.4.665.35","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.214.1.r00ja28273"},{"key":"2018112909340808000_42.4.665.36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq102"},{"key":"2018112909340808000_42.4.665.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203055"},{"key":"2018112909340808000_42.4.665.38","first-page":"231","article-title":"Intravenous methylprednisolone pulse therapy in ankylosing spondylitis","volume":"32","author":"Ejstrup","year":"1985","journal-title":"Dan Med Bull"},{"key":"2018112909340808000_42.4.665.39","doi-asserted-by":"publisher","DOI":"10.3109\/03009749209095085"},{"key":"2018112909340808000_42.4.665.40","first-page":"86","article-title":"Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis","volume":"33","author":"Zink","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.41","first-page":"CD004524","article-title":"Methotrexate for ankylosing spondylitis","volume":"2","author":"Chen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2018112909340808000_42.4.665.42","doi-asserted-by":"crossref","unstructured":"Chen J Liu C . Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2005;CD004800.","DOI":"10.1002\/14651858.CD004800.pub2"},{"key":"2018112909340808000_42.4.665.43","first-page":"722","article-title":"Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials","volume":"33","author":"Chen","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.44","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2619-6"},{"key":"2018112909340808000_42.4.665.45","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2018112909340808000_42.4.665.46","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.139667"},{"key":"2018112909340808000_42.4.665.47","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes142"},{"key":"2018112909340808000_42.4.665.48","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.036491"},{"key":"2018112909340808000_42.4.665.49","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019174"},{"key":"2018112909340808000_42.4.665.50","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150995"},{"key":"2018112909340808000_42.4.665.51","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0787-7"},{"key":"2018112909340808000_42.4.665.52","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1964.03070100037007"},{"key":"2018112909340808000_42.4.665.53","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270403"},{"key":"2018112909340808000_42.4.665.54","first-page":"241","article-title":"Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome","volume":"22","author":"Abu-Shakra","year":"1995","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.55","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes001"},{"key":"2018112909340808000_42.4.665.56","first-page":"1957","article-title":"The use of sulfasalazine in psoriatic arthritis: a clinic experience","volume":"25","author":"Rahman","year":"1998","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.57","doi-asserted-by":"publisher","DOI":"10.1002\/art.20253"},{"key":"2018112909340808000_42.4.665.58","doi-asserted-by":"publisher","DOI":"10.1097\/00124743-200112000-00003"},{"key":"2018112909340808000_42.4.665.59","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.140.10.1288"},{"key":"2018112909340808000_42.4.665.60","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/acr.21848","article-title":"Leflunomide in psoriatic arthritis: results from a large European prospective observational study","volume":"65","author":"Behrens","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2018112909340808000_42.4.665.61","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121192"},{"key":"2018112909340808000_42.4.665.62","doi-asserted-by":"publisher","DOI":"10.1002\/art.27394"},{"key":"2018112909340808000_42.4.665.63","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes026"},{"key":"2018112909340808000_42.4.665.64","first-page":"672","article-title":"The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab","volume":"29","author":"Heldmann","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909340808000_42.4.665.65","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202698"},{"key":"2018112909340808000_42.4.665.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.02.014"},{"key":"2018112909340808000_42.4.665.67","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-013-2263-x"},{"key":"2018112909340808000_42.4.665.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.04.017"},{"key":"2018112909340808000_42.4.665.69","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091042"},{"key":"2018112909340808000_42.4.665.70","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091043"},{"key":"2018112909340808000_42.4.665.71","doi-asserted-by":"crossref","first-page":"289845","DOI":"10.1155\/2013\/289845","article-title":"Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study","volume":"2013","author":"M\u00f6rck","year":"2013","journal-title":"Mediators Inflamm"},{"key":"2018112909340808000_42.4.665.72","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1616-x"},{"key":"2018112909340808000_42.4.665.73","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1157-3"},{"key":"2018112909340808000_42.4.665.74","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203201"},{"key":"2018112909340808000_42.4.665.75","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202389"},{"key":"2018112909340808000_42.4.665.76","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201010"},{"key":"2018112909340808000_42.4.665.77","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.147033"},{"key":"2018112909340808000_42.4.665.78","first-page":"80","article-title":"The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept","volume":"29","author":"Lubrano","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909340808000_42.4.665.79","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201766"},{"key":"2018112909340808000_42.4.665.80","doi-asserted-by":"publisher","DOI":"10.1002\/art.38014"},{"key":"2018112909340808000_42.4.665.81","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200358"},{"key":"2018112909340808000_42.4.665.82","first-page":"624","article-title":"Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis","volume":"29","author":"Kimel","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909340808000_42.4.665.83","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100213"},{"key":"2018112909340808000_42.4.665.84","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090242"},{"key":"2018112909340808000_42.4.665.85","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq129"},{"key":"2018112909340808000_42.4.665.86","doi-asserted-by":"publisher","DOI":"10.1186\/ar2953"},{"key":"2018112909340808000_42.4.665.87","doi-asserted-by":"publisher","DOI":"10.1186\/ar3054"},{"key":"2018112909340808000_42.4.665.88","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-011-0557-x"},{"key":"2018112909340808000_42.4.665.89","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202533"},{"key":"2018112909340808000_42.4.665.90","doi-asserted-by":"publisher","DOI":"10.1002\/art.23969"},{"key":"2018112909340808000_42.4.665.91","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.154799"},{"key":"2018112909340808000_42.4.665.92","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200308"},{"key":"2018112909340808000_42.4.665.93","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes251"},{"key":"2018112909340808000_42.4.665.94","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.148890"},{"key":"2018112909340808000_42.4.665.95","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204231"},{"key":"2018112909340808000_42.4.665.96","unstructured":"Brooks M . Medscape: FDA clears certolizumab (cimzia) for ankylosing spondylitis. [Internet. Accessed January 13, 2015.] Available from: www.medscape.com\/viewarticle\/812822"},{"key":"2018112909340808000_42.4.665.97","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket187"},{"key":"2018112909340808000_42.4.665.98","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202245"},{"key":"2018112909340808000_42.4.665.99","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H"},{"key":"2018112909340808000_42.4.665.100","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380507"},{"key":"2018112909340808000_42.4.665.101","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130163"},{"key":"2018112909340808000_42.4.665.102","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"2018112909340808000_42.4.665.103","doi-asserted-by":"publisher","DOI":"10.1002\/art.20967"},{"key":"2018112909340808000_42.4.665.104","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100069"},{"key":"2018112909340808000_42.4.665.105","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.106","doi-asserted-by":"publisher","DOI":"10.1002\/art.24403"},{"key":"2018112909340808000_42.4.665.107","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120254"},{"key":"2018112909340808000_42.4.665.108","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203696"},{"key":"2018112909340808000_42.4.665.109","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094946"},{"key":"2018112909340808000_42.4.665.110","unstructured":"Health Canada . [Internet. Accessed January 16, 2015.] Available from: www.hc-sc.gc.ca\/index-eng.php"},{"key":"2018112909340808000_42.4.665.111","doi-asserted-by":"publisher","DOI":"10.1002\/art.23167"},{"key":"2018112909340808000_42.4.665.112","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken207"},{"key":"2018112909340808000_42.4.665.113","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.022582"},{"key":"2018112909340808000_42.4.665.114","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04050.x"},{"key":"2018112909340808000_42.4.665.115","doi-asserted-by":"publisher","DOI":"10.1186\/ar3350"},{"key":"2018112909340808000_42.4.665.116","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"2018112909340808000_42.4.665.117","doi-asserted-by":"publisher","DOI":"10.1002\/art.22379"},{"key":"2018112909340808000_42.4.665.118","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"2018112909340808000_42.4.665.119","doi-asserted-by":"publisher","DOI":"10.1002\/art.23333"},{"key":"2018112909340808000_42.4.665.120","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.073544"},{"key":"2018112909340808000_42.4.665.121","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201933"},{"key":"2018112909340808000_42.4.665.122","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.131797"},{"key":"2018112909340808000_42.4.665.123","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken094"},{"key":"2018112909340808000_42.4.665.124","first-page":"1010","article-title":"Switching between tumour necrosis factor blockers in spondyloarthritis: a retrospective monocentre study of 222 patients","volume":"29","author":"Dadoun","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909340808000_42.4.665.125","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket249"},{"key":"2018112909340808000_42.4.665.126","doi-asserted-by":"publisher","DOI":"10.1002\/art.22236"},{"key":"2018112909340808000_42.4.665.127","doi-asserted-by":"publisher","DOI":"10.1002\/art.37876"},{"key":"2018112909340808000_42.4.665.128","doi-asserted-by":"publisher","DOI":"10.1186\/ar2670"},{"key":"2018112909340808000_42.4.665.129","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203018"},{"key":"2018112909340808000_42.4.665.130","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq377"},{"key":"2018112909340808000_42.4.665.131","doi-asserted-by":"publisher","DOI":"10.1186\/ar1881"},{"key":"2018112909340808000_42.4.665.132","doi-asserted-by":"publisher","DOI":"10.1002\/art.27383"},{"key":"2018112909340808000_42.4.665.133","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120201"},{"key":"2018112909340808000_42.4.665.134","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"2018112909340808000_42.4.665.135","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.515804"},{"key":"2018112909340808000_42.4.665.136","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204741"},{"key":"2018112909340808000_42.4.665.137","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.145946"},{"key":"2018112909340808000_42.4.665.138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2011.02.018"},{"key":"2018112909340808000_42.4.665.139","doi-asserted-by":"publisher","DOI":"10.1002\/art.30176"},{"key":"2018112909340808000_42.4.665.140","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203559"},{"key":"2018112909340808000_42.4.665.141","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110265"},{"key":"2018112909340808000_42.4.665.142","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126706"},{"key":"2018112909340808000_42.4.665.143","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes432"},{"key":"2018112909340808000_42.4.665.144","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2011.06.011"},{"key":"2018112909340808000_42.4.665.145","doi-asserted-by":"publisher","DOI":"10.1002\/art.24899"},{"key":"2018112909340808000_42.4.665.146","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.020800"},{"key":"2018112909340808000_42.4.665.147","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem302"},{"key":"2018112909340808000_42.4.665.148","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023176"},{"key":"2018112909340808000_42.4.665.149","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep174"},{"key":"2018112909340808000_42.4.665.150","first-page":"481","article-title":"Prevalence and characteristics of hip involvement in spondyloarthritis: a single-centre observational study of 275 patients","volume":"30","author":"Burki","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909340808000_42.4.665.151","doi-asserted-by":"publisher","DOI":"10.1016\/S0883-5403(00)91155-0"},{"key":"2018112909340808000_42.4.665.152","first-page":"1862","article-title":"Total hip arthroplasty in ankylosing spondylitis: outcome in 340 patients","volume":"28","author":"Sweeney","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.153","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2007.07.014"},{"key":"2018112909340808000_42.4.665.154","doi-asserted-by":"publisher","DOI":"10.1054\/arth.2002.32170"},{"key":"2018112909340808000_42.4.665.155","doi-asserted-by":"publisher","DOI":"10.1080\/00016470152846538"},{"key":"2018112909340808000_42.4.665.156","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2106\/00004623-199708000-00010","article-title":"Longterm results of total hip replacement in young patients who had ankylosing spondylitis. Eighteen to thirty-year results with survivorship analysis","volume":"79","author":"Sochart","year":"1997","journal-title":"J Bone Joint Surg Am"},{"key":"2018112909340808000_42.4.665.157","doi-asserted-by":"publisher","DOI":"10.1016\/S0883-5403(96)80180-X"},{"key":"2018112909340808000_42.4.665.158","first-page":"1704","article-title":"Total hip arthroplasty in patients with ankylosing spondylitis: longterm followup","volume":"22","author":"Shih","year":"1995","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.159","doi-asserted-by":"crossref","unstructured":"Walker LG Sledge CB . Total hip arthroplasty in ankylosing spondylitis. Clin Orthop Relat Res 1991:198\u2013204.","DOI":"10.1097\/00003086-199101000-00028"},{"key":"2018112909340808000_42.4.665.160","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2106\/00004623-199072060-00006","article-title":"Total hip replacement for patients who have ankylosing spondylitis. The importance of the formation of heterotopic bone and of the durability of fixation of cemented components","volume":"72","author":"Kilgus","year":"1990","journal-title":"J Bone Joint Surg Am"},{"key":"2018112909340808000_42.4.665.161","first-page":"955","article-title":"The outcome of 138 total hip replacements and 12 revisions in ankylosing spondylitis: high success rate after a mean followup of 7.5 years","volume":"16","author":"Calin","year":"1989","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.162","doi-asserted-by":"crossref","unstructured":"Sundaram NA Murphy JC . Heterotopic bone formation following total hip arthroplasty in ankylosing spondylitis. Clin Orthop Relat Res 1986:223\u20136.","DOI":"10.1097\/00003086-198606000-00039"},{"key":"2018112909340808000_42.4.665.163","doi-asserted-by":"publisher","DOI":"10.1097\/BSD.0b013e3181a5abde"},{"key":"2018112909340808000_42.4.665.164","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.C.01472"},{"key":"2018112909340808000_42.4.665.165","doi-asserted-by":"publisher","DOI":"10.1097\/01.brs.0000216479.09250.96"},{"key":"2018112909340808000_42.4.665.166","doi-asserted-by":"publisher","DOI":"10.1097\/00007632-200203150-00010"},{"key":"2018112909340808000_42.4.665.167","doi-asserted-by":"publisher","DOI":"10.1097\/01.brs.0000250663.12224.d9"},{"key":"2018112909340808000_42.4.665.168","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0b013e318250dc95"},{"key":"2018112909340808000_42.4.665.169","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-008-0590-3"},{"key":"2018112909340808000_42.4.665.170","doi-asserted-by":"crossref","unstructured":"Weale AE Marsh CH Yeoman PM . Secure fixation of lumbar osteotomy. Surgical experience with 50 patients. Clin Orthop Relat Res 1995:216\u201322.","DOI":"10.1097\/00003086-199512000-00033"},{"key":"2018112909340808000_42.4.665.171","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1302\/0301-620X.77B1.7822367","article-title":"Closing-wedge posterior osteotomy for ankylosing spondylitis. Partial corporectomy and transpedicular fixation in 22 cases","volume":"77","author":"van Royen","year":"1995","journal-title":"J Bone Joint Surg Br"},{"key":"2018112909340808000_42.4.665.172","doi-asserted-by":"crossref","unstructured":"Hehne HJ Zielke K Bohm H . Polysegmental lumbar osteotomies and transpedicled fixation for correction of long-curved kyphotic deformities in ankylosing spondylitis. Report on 177 cases. Clin Orthop Relat Res 1990:49\u201355.","DOI":"10.1097\/00003086-199009000-00008"},{"key":"2018112909340808000_42.4.665.173","doi-asserted-by":"publisher","DOI":"10.1097\/01.bsd.0000211252.67576.d9"},{"key":"2018112909340808000_42.4.665.174","doi-asserted-by":"publisher","DOI":"10.1097\/01.brs.0000170300.17082.49"},{"key":"2018112909340808000_42.4.665.175","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0b013e318074c3ce"},{"key":"2018112909340808000_42.4.665.176","doi-asserted-by":"publisher","DOI":"10.1097\/01.brs.0000219870.31561.c2"},{"key":"2018112909340808000_42.4.665.177","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3182514043"},{"key":"2018112909340808000_42.4.665.178","doi-asserted-by":"publisher","DOI":"10.1002\/art.22893"},{"key":"2018112909340808000_42.4.665.179","doi-asserted-by":"publisher","DOI":"10.1002\/art.22897"},{"key":"2018112909340808000_42.4.665.180","first-page":"287","article-title":"Exercise therapy in juvenile idiopathic arthritis: a Cochrane review","volume":"44","author":"Takken","year":"2008","journal-title":"Eur J Phys Rehabil Med"},{"key":"2018112909340808000_42.4.665.181","doi-asserted-by":"publisher","DOI":"10.2340\/16501977-1051"},{"key":"2018112909340808000_42.4.665.182","doi-asserted-by":"publisher","DOI":"10.1002\/art.23008"},{"key":"2018112909340808000_42.4.665.183","first-page":"943","article-title":"Efficacy of custom foot orthotics in improving pain and functional status in children with juvenile idiopathic arthritis: a randomized trial","volume":"32","author":"Powell","year":"2005","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.184","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-39925"},{"key":"2018112909340808000_42.4.665.185","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21947"},{"key":"2018112909340808000_42.4.665.186","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-012-2487-y"},{"key":"2018112909340808000_42.4.665.187","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker441"},{"key":"2018112909340808000_42.4.665.188","first-page":"1157","article-title":"Intraarticular corticosteroid injections of the temporomandibular joint in juvenile idiopathic arthritis","volume":"35","author":"Ringold","year":"2008","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.189","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-007-0457-6"},{"key":"2018112909340808000_42.4.665.190","first-page":"2100","article-title":"Factors affecting the efficacy of intraarticular corticosteroid injection of knees in juvenile idiopathic arthritis","volume":"28","author":"Ravelli","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.191","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.10.941"},{"key":"2018112909340808000_42.4.665.192","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199805)41:5<808::AID-ART6>3.0.CO;2-T"},{"key":"2018112909340808000_42.4.665.193","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.064717"},{"key":"2018112909340808000_42.4.665.194","doi-asserted-by":"publisher","DOI":"10.1007\/BF01450892"},{"key":"2018112909340808000_42.4.665.195","first-page":"360","article-title":"Sulfasalazine therapy for juvenile rheumatoid arthritis","volume":"23","author":"Imundo","year":"1996","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.196","first-page":"489","article-title":"[Treatment of juvenile spondyloarthropathies with sulfasalazine]","volume":"60","author":"Job-Deslandre","year":"1993","journal-title":"Rev Rhum Ed Fr"},{"key":"2018112909340808000_42.4.665.197","first-page":"658","article-title":"[Treatment of juvenile spondylarthritis and reactive arthritis with sulfasalazine]","volume":"140","author":"Suschke","year":"1992","journal-title":"Monatsschr Kinderheilkd"},{"key":"2018112909340808000_42.4.665.198","first-page":"110","article-title":"Sulfasalazine therapy for juvenile rheumatoid arthritis","volume":"101","author":"Chen","year":"2002","journal-title":"J Formos Med Assoc"},{"key":"2018112909340808000_42.4.665.199","first-page":"845","article-title":"Sulfasalazine for the management of juvenile rheumatoid arthritis","volume":"28","author":"Brooks","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.200","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-4857-7_50"},{"key":"2018112909340808000_42.4.665.201","doi-asserted-by":"publisher","DOI":"10.1007\/BF02231781"},{"key":"2018112909340808000_42.4.665.202","first-page":"80","article-title":"Sulphasalazine and Delagil\u2014a comparative study in patients with juvenile chronic arthritis","volume":"37","author":"Hoza","year":"1991","journal-title":"Acta Univ Carol Med"},{"key":"2018112909340808000_42.4.665.203","first-page":"880","article-title":"Sulfasalazine treatment in juvenile chronic arthritis: An open study","volume":"18","author":"Joos","year":"1991","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.204","first-page":"201","article-title":"A multicentre pilot study of sulphasalazine in juvenile chronic arthritis","volume":"9","author":"Ansell","year":"1991","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909340808000_42.4.665.205","first-page":"124","article-title":"Sulphasalazine in the treatment of juvenile rheumatoid arthritis: a preliminary open trial","volume":"13","author":"Ozdogan","year":"1986","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.206","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204163261602"},{"key":"2018112909340808000_42.4.665.207","doi-asserted-by":"publisher","DOI":"10.1002\/art.20288"},{"key":"2018112909340808000_42.4.665.208","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8<1849::AID-ANR22>3.0.CO;2-F"},{"key":"2018112909340808000_42.4.665.209","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21697"},{"key":"2018112909340808000_42.4.665.210","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075895"},{"key":"2018112909340808000_42.4.665.211","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-1116-7"},{"key":"2018112909340808000_42.4.665.212","first-page":"113","article-title":"High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis","volume":"13","author":"Reiff","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909340808000_42.4.665.213","first-page":"297","article-title":"Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype","volume":"9","author":"Halle","year":"1991","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909340808000_42.4.665.214","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041810"},{"key":"2018112909340808000_42.4.665.215","doi-asserted-by":"publisher","DOI":"10.1002\/art.20861"},{"key":"2018112909340808000_42.4.665.216","first-page":"S319","article-title":"Efficacy, safety, and tolerability of infliximab in juvenile-onset spondyloarthropathies (JO-SpA): results of a three-month, randomized, double-blind, placebo-controlled trial phase","volume":"56","author":"Burgos-Vargas","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2018112909340808000_42.4.665.217","doi-asserted-by":"publisher","DOI":"10.1002\/art.21121"},{"key":"2018112909340808000_42.4.665.218","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.03.008"},{"key":"2018112909340808000_42.4.665.219","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110145"},{"key":"2018112909340808000_42.4.665.220","first-page":"2055","article-title":"Prolonged efficacy of etanercept in refractory enthesitis-related arthritis","volume":"31","author":"Henrickson","year":"2004","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.221","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0971"},{"key":"2018112909340808000_42.4.665.222","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-003-0378-0"},{"key":"2018112909340808000_42.4.665.223","first-page":"1186","article-title":"Radiologic improvement of juvenile idiopathic arthritis-enthesitis-related arthritis following anti-tumor necrosis factor-alpha blockade with etanercept","volume":"33","author":"Tse","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909340808000_42.4.665.224","doi-asserted-by":"publisher","DOI":"10.1002\/art.38414"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.141001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T06:26:48Z","timestamp":1717741608000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.141001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,15]]},"references-count":224,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4,1]]},"published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.3899\/jrheum.141001"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.141001","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,15]]}}}